Vivimed Labs (NSE:VIVIMEDLAB) Risk Assessment


NSE:VIVIMEDLAB Vivimed Labs Ltd NSE:VIVIMEDLAB
42 GF Score
Price ₹5.41
GF Value ₹2.55
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Vivimed Labs Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Vivimed Labs is: High Risk: High uncertainty with risk-return tradeoff.

Vivimed Labs  (NSE:VIVIMEDLAB) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Vivimed Labs Risk Assessment Related Terms

NSE:VIVIMEDLAB vs ZTS, UTHR: Risk Assessment Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vivimed Labs's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivimed Labs Risk Assessment vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivimed Labs's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Vivimed Labs's Risk Assessment falls into.


NSE:VIVIMEDLAB
42GF Score
Vivimed Labs Ltd NSE:VIVIMEDLAB
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued. The current stock price of ₹5.41 is trading 112.2% above its estimated GF Value™ of ₹2.55. GuruFocus considers Vivimed Labs to be Significantly Overvalued.

Key valuation signals for NSE:VIVIMEDLAB:

  • Risk Assessment:
  • GF Value™: ₹2.55 vs. price of ₹5.41 (112.2% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivimed Labs Business Description

Other Exchanges 532660:India
Address Green Lands, Beside The Plaza Hotel, D.No. 6-3-866/1/G1, 3rd & 4th Floor, GMR Towers, Begumpet, Hyderabad, TG, IND, 500016
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
42GF Score

Get the complete analysis for NSE:VIVIMEDLAB

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5.41
Price
₹2.55
GF Value